Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention

500 patients undergoing percutaneous coronary intervention (PCI) with planned use of a glycoprotein (GP) IIb/IIIa inhibitor

Achieving ≥95% platelet function inhibition at 10 minutes after initiation of GP IIb/IIIa antagonist therapy (measured by Ultegra Rapid Platelet Function Assay)

Not achieving ≥95% platelet function inhibition at 10 minutes (<95% inhibition)

Major adverse cardiac events (MACEs: composite of death, myocardial infarction, and urgent target vessel revascularization)composite